Skip to main content
Clinical Trials/NCT03604861
NCT03604861
Completed
Not Applicable

Remission From Chronic Opioid Use: Studying Environmental and SocioEconomic Factors on Recovery-The RECOVER Study®

Indivior Inc.35 sites in 1 country534 target enrollmentAugust 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Opioid-use Disorder
Sponsor
Indivior Inc.
Enrollment
534
Locations
35
Primary Endpoint
Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Previous 28 Days at Month 24
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The RECOVER Study will examine clinical, environmental and socioeconomic factors in recovery from opioid use disorder (OUD) over a 24-month period following exit from a Phase III clinical program for a buprenorphine extended-release injection (RBP-6000). The study population will consist of participants from studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003).

The RECOVER study will characterize OUD subjects' recovery process as they transition from the controlled clinical trial environment to the real world setting.

Registry
clinicaltrials.gov
Start Date
August 2015
End Date
March 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects who received at least one injection in RBP-6000 or placebo in the Phase III clinical program which includes study protocols NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003) and either withdrew from or completed these studies.
  • Ability to comply with study protocol requirements for data collection and provide informed consent.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Previous 28 Days at Month 24

Time Frame: Month 24

Based on self-reported abstinence from opioids using the National Survey on Drug Use and Health (NSDUH).

Change from Baseline in Percentage of Participants Who Reported Abstinent From Opioids For the Previous 28 Days At Months 3, 6, 9, 12, 15, 18, 21, 24

Time Frame: Baseline (Day 1), Months 3, 6, 9, 12, 15, 18, 21, 24

Based on self-reported abstinence from opioids using the National Survey on Drug Use and Health (NSDUH).

Change from Baseline in Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days At Months 3, 6, 9, 12, 15, 18, 21, 24

Time Frame: Baseline (Day 1), Months 3, 6, 9, 12, 15, 18, 21, 24

Based on self-reported abstinence from opioids using the National Survey on Drug Use and Health (NSDUH).

Change from Baseline in Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Confirmed by UDS At Months 3, 6, 9, 12, 15, 18, 21, 24

Time Frame: Baseline (Day 1), Months 3, 6, 9, 12, 15, 18, 21, 24

Based on self-reported abstinence from opioids (using NSDUH), and confirmed by UDS.

Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days and Confirmed by Urine Drug Screen (UDS) at Month 24

Time Frame: Month 24

Based on self-reported abstinence from opioids (using NSDUH), and confirmed by UDS.

Study Sites (35)

Loading locations...

Similar Trials